Led by a professional team in healthcare with a proven track record of over 40 million fundraising experience and 5 successful busines exits, NovaXS is a therapeutic startup focused on improving treatment efficacy through advanced drug delivery platform and innovative CRISPR gene therapy nanoparticle delivery.
Our patent-pending technology, Telosis, is an IoT needle-free injector that allows patients to self-administer biologics subcutaneously or intramuscularly and tracks long-term treatment progress. Our new drug candidate, Nova-21, is a biodegradable gene therapy nanoparticle delivery for Duchenne Muscular Dystrophy discovered by UC Berkeley QB3 Laboratory head, Professor Irina Conboy.
Our patent-pending technology, Telosis, is an IoT needle-free injector that allows patients to self-administer biologics subcutaneously or intramuscularly and tracks long-term treatment progress. Our new drug candidate, Nova-21, is a biodegradable gene therapy nanoparticle delivery for Duchenne Muscular Dystrophy discovered by UC Berkeley QB3 Laboratory head, Professor Irina Conboy.
Location: United States, California, Berkeley
Employees: 1-10
Total raised: $1.5M
Founded date: 2021
Investors 3
| Date | Name | Website |
| - | Berkeley S... | skydeck.be... |
| 09.02.2023 | Techstars | techstars.... |
| - | Health Eng... | readysethe... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 31.03.2022 | - | $1.5M | - |
Mentions in press and media 7
| Date | Title | Description |
| 16.10.2023 | Monoclonal Antibodies Market Size Projections Exhibit a CAGR of 12.0%, Likely to Attain a Value of USD 463.0 Billion by 2030 | - |
| 27.03.2023 | NovaXS Biotech Corp. joins Techstars Healthcare Accelerator | Drug delivery platform startup gains access to startup resources and research BOSTON, MA, UNITED STATES, March 27, 2023/EINPresswire.com/ -- NovaXS Biotech Corp. (NovaXS), developers of an in-home needle-free drug delivery platform, have jo... |
| 14.12.2022 | NovaXS Biotech Corp Aims to Raise $1M to Support Product Development and Testing | NovaXS Needle Free Injector Telosis Crowdfunding campaign invites public to invest in needle-free injection platform CHICAGO, IL, USA, December 14, 2022 /EINPresswire.com/ -- NovaXS Biotech Corp. (NovaXS), developers of an in-home and needl... |
| 30.09.2022 | Mental Healthcare and Drug Delivery Focus at the HealthTech & BioTech Unicorn Battle Q4 2022 | This Unicorn Battle in the Q4 2022 season commenced – HealthTech and BioTech 10 international startups wrestled for the winner’s title Sense Neuro Diagnostics from the USA became the decisive winner September 23 marked the third Battle of ... |
| 31.03.2022 | NovaXS Biotech raises $1.5M to make injection therapy needle-free | A startup spawned from a lab at the University of California, Berkeley has won investor support to work on its patented needle-free injector, which it hopes can make therapies that traditionally require daily self-administered medicines les... |
| 11.11.2021 | Hardtech Innovation Center mHUB Announces Portfolio Teams of Premier MedTech Accelerator Cohort | mHUB MedTech accelerator cohort meets in Chicago for 6-month program “As a program mentor, I’m excited to welcome to the city a group of hardtech focused healthcare startups that will help revolutionize how we diagnose and manage patients a... |
| - | Биотех-стартап NovaXS привлек $1,5 млн на разработку инновационного безыгольного инъектора | 3 комментарии 21 просмотров Биотех-стартап NovaXS занимается разработкой инновационного безыгольного инъектора - девайса, с помощью которого можно делать уколы и проводить некоторые инвазивные медицинские манипуляции без использования иглы.... |